PA-BOOMI
Boomi™, the intelligent integration and automation leader, is thrilled to announce Boomi World is back. The company’s highly anticipated industry event will take place May 6-9, 2024 at the Sheraton Denver Downtown Hotel in Denver, Colorado. Boomi World 2024 promises to be a transformative experience, bringing together industry leaders, technology experts, and visionary professionals to explore the latest trends and innovations in AI, integration, and automation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240409873041/en/
Boomi World 2024 User Conference to Feature Deion “Coach Prime” Sanders (Graphic: Business Wire)
Emceed by technology industry veteran and correspondent Lisa Martin, Boomi World 2024 will feature esteemed guest speakers, including:
- Collegiate Head Football Coach and Pro Football Hall of Famer Deion Sanders
- Tropicana CIO Jeff Lischett
- Australian Red Cross CIO Brett Wilson
- Fever-Tree Head of Technology Kate Stables
- KORE Wireless Senior Director of Enterprise Applications Nicki Brock
- OSI Digital CMO Karen Dosanjh
- Gartner Senior Director Analyst John Santoro
- BARC US CEO Shawn Rogers
- IDC Research Director/Analyst Shari Lava
- Boomi CEO Steve Lucas
- Boomi Chief Product and Technology Officer Ed Macosky
- Boomi CTO Matt McLarty; and more!
Boomi World 2024 will provide attendees the opportunity to experience the power of AI-driven connection. Boomi’s customers and partners will discover how Boomi’s intelligent integration and automation platform helps organizations tame IT complexity, drive radical innovation, and synchronize everything, everywhere.
Event Highlights:
1. Robust Agenda
Boomi World 2024 boasts a dynamic and comprehensive agenda, featuring thought-provoking sessions, hands-on workshops, and engaging panel discussions. Attendees will have the opportunity to dive into the latest advancements in integration technology, best practices, and success stories from forward-thinking enterprises across industries that have transformed their organizations with Boomi.
2. Special Guest Deion Sanders
Boomi welcomes Deion Sanders, aka “Coach Prime,” as its special guest speaker.
As head coach from 2020-2022, Sanders led Jackson State University (JSU) to back-to-back SWAC Championships, and won back-to-back SWAC Coach of the Year honors. During his time at JSU, the Tigers had a 27-6 record, including a perfect regular season in 2022. In 2021, he was named the Eddie Robinson Coach of the Year.
Sanders is a member of the Pro Football Hall of Fame, a two-time Super Bowl champion, and eight-time Pro Bowler. He played 14 years in the NFL for the Atlanta Falcons, San Francisco 49ers, Dallas Cowboys, Washington Commanders, and Baltimore Ravens. Sanders is the only person in professional sports history to play in both the World Series and the Super Bowl.
After retiring from professional sports, Sanders became an analyst for CBS Sports and NFL Network, and now offers his insights and opinions on the Pro Football Show on Barstool Sports. He has produced and/or appeared in a variety of television shows, including Tiny House Nation, Grandfathered, Moesha, Running Wild With Bear Grylls, Lip Sync Battle, The League, 30 For 30: Deion’s Double Play, Deion’s Family Playbook, and, most recently, Coach Prime, a docuseries on Prime Video which follows Sanders and his college football journey.
3. Exclusive Announcements
Be the first to hear Boomi's latest product and platform updates, roadmap, and strategic initiatives. Boomi World 2024 will feature exclusive announcements that will shape the future of AI, integration, and automation.
4. Pre-Conference Training and Partner Summit
Starting on May 6, Boomi World will provide optional one and two-day Pre-Conference Training and certification courses, with in-depth sessions covering the various Platform Services within the Boomi platform, including Integration, runtime architecture, API Management, and Master Data Hub.
Taking place on May 7, the Boomi Partner Summit provides partners an exclusive look at the future of the Boomi ecosystem. Partners will get a sneak peek at upcoming announcements and gain access to go-to-market resources designed to drive growth while helping customers more quickly and easily connect, automate, and modernize their digital landscape.
5. 40+ Breakout Sessions
Boomi World will offer more than 40 breakout sessions focused on the following four tracks:
Hands-On Labs will offer attendees the opportunity to explore what’s new in the Boomi platform, get creative with AI, and learn about Retrieval-Augmented Generation — including how to set up a RAG using Boomi.
Developer/Technical track, which will include sessions on popular integration use cases, runtime monitoring, error-handling strategies, master data management, and “Boomi on Boomi” solutions.
CIO/Executive track for executive attendees — or anyone interested in topics designed to appeal to CIOs — which will feature sessions on risk management, Boomi platform security, and AI readiness.
Innovation track, which will include a wide range of sessions from customers, partners, industry analysts, and Boomi technology experts designed to showcase the myriad ways the Boomi platform can be used to connect and transform organizations.
6. Networking Opportunities
Connect with like-minded professionals, industry experts, and Boomi partners during dedicated networking sessions. Boomi World 2024 provides a unique platform to foster collaboration, share ideas, and build valuable relationships within the integration, automation, and connectivity community.
Sponsors:
A special thanks to Boomi’s partner sponsors for helping make Boomi World 2024 possible, including Cognizant and Infosys as Diamond sponsors, and Apica, Kitepipe, LTIMindtree, R Systems, TCS, and United Techno as Platinum sponsors.
Registration:
Registration is now open. Secure your spot at Boomi World 2024 by visiting BoomiWorld.com.
To join the Boomi World conversation on social media, use #BoomiWorld.
Additional Resources
- Learn more about the Boomi platform
- Follow Boomi on LinkedIn, X (Twitter), Facebook, and YouTube
About Boomi
Boomi powers the future of business with intelligent integration and automation. As a category-leading, global software as a service (SaaS) company, Boomi celebrates more than 20,000 global customers and a worldwide network of 800 partners. Organizations turn to Boomi’s award-winning platform to connect their applications, data, and people to accelerate digital transformation. For more information, visit boomi.com.
© 2024 Boomi, LP. Boomi, the ‘B’ logo, and Boomiverse are trademarks of Boomi, LP or its subsidiaries or affiliates. All rights reserved. Other names or marks may be the trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240409873041/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom